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INTRODUCTION 
The budding interest and challenges in the delivery of 
active ingredients through skin has generated number of 
advancement throughout recent years with a focus on 
emerging novel application that offers many advantage 
such as reduced side effects, less frequent administration 
to produce the desired constant plasma concentration 
associated with patient compliance, elimination of the 
first pass effect, sustained drug delivery and interruption 
of treatment when necessary 1-3. 
Carvedilol is widely used for the therapeutic 
management of hypertension and congestive heart 
failure. It is drug of choice for hypertension but it has 
several drawbacks such as short biological half life (2-8 
hours), readily metabolized in liver primarily by 
cytochrome P450 isoenzyme (CYP 206 and CYP 209) 
and has an oral bioavailability of 25-30 %. These factors 
in addition to its low molecular weight (406.05), low 
melting point (117°C), high lipid solubility and effective 
in low plasma concentration necessitates the formulation 
of sustained release transdermal drug delivery system for 
carvedilol 2-4. 
Polymers such as Ethyl cellulose, PVP K-30, HPMC 
K15M and Carbopol 934 were selected on the basis of 
their adhering property and non toxicity to prepare 
Carvedilol transdermal patches. Transdermal drug 
delivery system is a most suitable system for a long-term 
treatment. Transdermal patches are prepared for a long 
period of time in a suitable dose to provide the treatment 
from a day to even up to seven days. In this study 
Carvedilol transdermal patches were prepared with 
combination of different polymers such as EC: PVP K-
30, EC: HPMC K-15M, EC: Carbopol-934. Formulations 
were further evaluated on the basis of their 
physicochemical properties, in-vitro drug permeation 
study and surface pH of the film. Physicochemical 
evaluation like thickness, weight variation, moisture 
content, drug content, folding endurance and flatness of 
the prepared transdermal patches were checked. A best 
patch among all the formulations was chosen on the basis 
of some evaluating parameters like maximum 
permeation, steady state flux and permeability 
coefficient. The main objective of this current study was 
to develop a potentially competitive product by 
optimizing and screening of various formulations 
variables to deliver the drug at a controlled rate across 
the skin. 
MATERIAL & METHODS 
Carvedilol, HPMC K4 M, PVP K30, Carbopol-934 were 
obtained as gift sample from Zydus Cadila, Ahmedabad, 
India. Ethyl cellulose, PEG 200, PVP and n-Octanol 
were procured from Cental Drug House (P) Ltd., 
Mumbai, India. Methanol, potassium dihydrogen 
phosphate, sodium chloride, chloroform were procured 
from Ranbaxy fine chemicals, Delhi, India. 
Determination of Partition Coefficient 
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The partition coefficient study of pure drug was 
performed using 50 ml n-octanol as the oil phase and 50 
ml phosphate buffers (PH 6.8) as the aqueous phase 5. 
The two phases were mixed in a separating funnel and 
were shaken continuously for 2 hrs by adding 50 mg of 
drug to achieve a complete partitioning of drug. The two 
phases were separated by centrifugation at 1500 rpm for 
5 min and the amounts of drug in both the phases were 
then analyzed spectrophotometrically at 242 nm. 
Preparation of Transdermal Film 
Drug free films were prepared by using the solvent 
evaporation method 2, 7, 8. In our earlier published paper 2 
the preparation of carvidilol transdermel films were 
optimized. The lower part of the Petri dish was wrapped 
with aluminum foil on which the backing membrane was 
casted by pouring 5ml of 4 % (w/v) polyvinyl alcohol 
(PVA) solution followed by drying at 60°C for 6 hr in 
hot air oven. After drying the backing membrane, 
different polymers were mixed in chloroform containing 
PEG-200 (30 % (w/w) of total polymer composition) and 
5ml of the polymer solution was poured in the Petridis 
and an inverted funnel was placed on the Petri dish to 
facilitate the evaporation of solvent at controlled manner. 
It was kept in an oven over a drying period of 6hr at 
40°C.The film was retrieved by cutting with surgical 
knife and kept in the desiccators for further evaluation. 
Drug loaded polymeric film was prepared in similar 
manner except that 16 mg (2.5 % w/w of total amount of 
polymers) of carvedilol dissolved in 5ml chloroform and 
it was added in the polymer solution containing 
plasticizer. Different formulations were prepared by 
using each polymer ratio of 6:4 and 8:2 of EC: PVP K-
30; EC: HPMC K15 and EC: Carbopol-934.
 
Table 1: Composition of Different Optimized drug loaded polymeric patches 
 
Evaluations of transdermal patches 
Thickness:
  
 The thickness 9 of the each patch was measured using 
screw gauge at different positions of the patch and the 
average was calculated. 
Weight variation:
  
Weight variation 10 was studied by individually weighing 
10 randomly selected patches (46.57 cm2). Such 
determination was performed for each formulation. 
Folding endurance:  
Folding endurance 11, 12 was determined by repeatedly 
folding one film at the same place till it broke. The 
number of times the film could be folded at the same 
place without breaking/ cracking gave the value of 
folding endurance. 
Moisture content:  
The patches were weighed 10-12 individually and kept in a 
desiccators containing activated silica at room 
temperature for 24 h. Then, the final weight was noted 
when there was no further change in the weight of the 
individual patch. The percentage of moisture content was 
calculated as a difference between initial and final 
weight with respect to final weight.  
Drug content uniformity:  
Three longitudinal strips were collected by cutting off 
three zones from each film: one from the centre, one 
from the left side and one from the right side 
11
. Patches 
of 0.64 cm2 areas from each zone were dissolved in 200 
ml of methanol and the volume was made up to 100 ml 
with same solvent and placed on electronic shaker for 1h 
to dissolve completely patches in methanol. The 
solutions were filtered through a 0.45 µm membrane, 
diluted suitably and absorbance were noted at 242 nm in 
a double beam UV-Visible spectrophotometer (Model-
1700, Shimadzu, Japan) against a blank that was 
prepared using a drug-free patch treated similarly after 
that drug content was calculated. 
Flatness study: 
 
Three longitudinal strips were collected by cutting off 
three zones from each film: one from the centre, one 
from the left side and one from the right side. The length 
of each strip was measured and the variation in length 
because of non-uniformity in flatness 11, 12 was measured 
S. 
No. 
Ingredients Formulations Code No. 
F1 F2 F3 F4 F5 F6 
1. Ethyl cellulose (EC) 
 
374.4 mg 499.2 mg 374.4 mg 499.2 mg 374.4 mg 499.2 mg 
2. Polyvinyl pyrrolidone K-30 
 (PVP K-30) 
249.6 mg 124.8 mg         ―      ―            ―     ― 
3. Hydroxypropyl methylcellulose K15M 
(HPMCK15M) 
    ―     ― 249.6 mg 124.8 mg     ―     ― 
4. Carbopol- 934     ―     ―     ―     ― 249.6 mg 124.8 mg 
5. Carvedilol (2.5% w/w of total polymer 
composition) 
16 mg 16 mg 16 mg 16 mg 16 mg 16 mg 
6. PVA (4% w/v of total polymer 
composition) 
5 ml 5 ml 5 ml 5 ml 5 ml 5 ml 
7. PEG-200 (30% w/v of total polymer 
composition) 
0.2 ml 0.2 ml 0.2 ml 0.2 ml 0.2 ml 0.2 ml 
8. Chloroform 15 ml 15 ml 15 ml 15 ml 15 ml 15 ml 
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by determining percent constriction, with 0% 
constriction equivalent to 100% flatness. 
 % Constriction = [(l1-l2) / l2] × 100 
Where, l1= initial length of each strip 
             l2= final length of each strip 
 
Drug and Polymers compatibility studies 
Differential Scanning Calorimetry:
 
 
The physicochemical compatibility between Carvedilol 
and polymers used in the patches was further studied by 
using differential scanning calorimetry (DSC Q10 V9.4 
Build 287, TA Instruments, USA). In DSC analysis, the 
samples were weighed (2 mg), hermetically sealed in 
flat-bottom aluminum pans, and heated over a 
temperature range of 50 to 150°C and 50 to 250°C in an 
atmosphere of nitrogen (50 mL/min) at a constant 
increasing rate of 10°C/min. The Thermograms obtained 
for Carvedilol, polymers and formulations of Carvedilol 
with polymers were compared 
13
. 
Fourier Transformed Infrared Spectroscopy:
 
 
The drug loaded transdermal film was analyzed by FT-
IR 13 to confirm the chemical interaction between the 
drug and polymer using the thin film.  IR spectrums were 
scanned on a model, RX-I FT-IR system, Perkin Elmer, 
USA in the range of 450- 4000cm-1. 
X-ray diffraction studies:  
X-ray diffraction studies were carried on physical 
mixture and drug containing transdermal film using the 
XRD technique 14-16 with model X’Pert-Pro 
diffractometer system PANalytical, The Netherlands. 
XRD studies were performed on the samples by expose 
them to Cu K-α-1 radiation (45kV, 40mA) and scanned 
from 2 to 50° 2θ, at a step size of 0.0170 2θ and a step 
time of 20.0271 s. 
Surface pH of the Film 
Transdermal patches were allowed to swell for 2 h at 
37˚C on the surface of an agar plate, prepared by 
dissolving 2% (w/v) agar in worm isotonic phosphate 
buffer of pH 5.5 under stirring and then pouring the 
solution into a Petri dish till gelling at room temperature. 
The surface pH was measured by means of a pH paper 
placed on the surface of the swollen patch. The mean of 
six reading was recorded. 
In-vitro Permeation Studies 
In vitro skin permeation studies 16-18 were performed by 
using a Franz diffusion cell with a receptor compartment 
capacity of 50 ml. The excised rat abdominal skin was 
mounted between the donor and receptor compartment of 
the diffusion cell. The formulated patches were placed 
over the skin and covered with paraffin film. The 
receptor compartment of diffusion cell was filled with 
phosphate buffer pH 7.4. The whole assembly was fixed 
on a magnetic stirrer and the solution in the receptor 
compartment was constantly and continuously stirred 
using magnetic beads at 50 rpm; the temperature was 
maintained at 37±0.5°C. The 2 ml aliquots were 
withdrawal at different time intervals (0, 30, 60, 90, 120, 
150 and 24 h) and analyzed for drug content 
spetrophotometrically by UV-Visible spectrophotometer 
(Model-1700, Shimadzu, Japan) at 242 nm. The receptor 
phase was replenished with an equal volume of 
phosphate buffer (37°C) at each sample withdrawal, the 
cumulative amount of drug permeated per square 
centimeter of patches were plotted against time.  
Scanning Electron Microscopy (SEM)  
Sample, for the SEM 18 was prepared by sprinkling the 
film on one side of a double adhesive stub. The stub was 
then coated with gold under vacuum (Fine Coat, in 
sputter, EC-1100). The transdermal patches were then 
observed under the scanning electron microscope (JEOL, 
JSM-6360 Scanning Electron Microscope, Japan) at 
15Kv. The samples include blank film (without drug), 
film before and after carrying out the permeation studies. 
Stability Studies  
Accelerated stability testing was conducted for 30 days 
at different temperatures: 4, 45, and 60°C. At specific 
intervals of time (Day 5, 10, 15, 20, 25, and 30), patches 
were taken out to assay their drug content, appearance, 
and texture. 
RESULTS AND DISCUSSION 
The partition coefficient of pure drug was proved its 
lipophilic characteristic and carvidilol is suitable to 
design a transdermal drug delivery system. The 
thicknesses for various formulations ranged between 
0.09±0.012 mm to 0.21±0.020 mm and which are 
tabulated in table 2. The deviation in the thickness was 
within the limits, as it gets confirmed by lower values of 
standard deviation. F-3 and F-4 formulations were 
prepared by EC and HPMC K15M and it has been seen 
with increases of HPMC content thickness was increased 
consistently but which was not observed in case of 
formulations fabricated by EC: Carbopol 934. It may be 
due to the gel forming properties of Carbopol, where as 
PVP do not contribute significantly towards thickness 
building as compared to HPMC and Carbopol.
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Table 2: Physicochemical Characteristics of Transdermal Patches 
Formulation 
Code No. 
Polymers  
Used 
 
 
Ratio 
of 
Polymer 
 
Thickness 
(mm) 
Mean ± 
S.D. 
Weight 
(mg) 
(46.57 
cm
2
) 
Mean ± 
S.D. 
Folding 
Endurance 
Moisture 
Content 
(%) 
Drug  
Content 
(mg) 
(0.64cm
2
) 
Mean ± 
S.D. 
Flatness 
( %) 
Surface 
pH 
F-1 EC:PVP 
K-30 
6:4 
 
0.09 ± 
0.012 
840 ± 
0.75 
>16 4.21 ± 3.4 0.232 ± 
0.021 
100 ≈ 6-7 
F-2 EC:PVP 
K-30 
8:2 
 
0.10 ± 
0.013 
839 ± 
0.92 
>14 3.17 ± 2.1 0.219 ± 
0.018 
100 ≈ 6-7 
F-3 EC:HPMC 
K15M 
6:4 
 
0.21± 
0.014 
840.7 
±1.62 
>10 5.06 ± 2.4 0.212 ± 
0.011 
100 ≈ 6-7 
F-4 EC:HPMC 
K15M 
8:2 
 
0.21± 
0.020 
840.9 ± 
1.52 
>8 4.12 ± 2.9 0.210 ± 
0.031 
100 ≈ 6-7 
F-5 EC:CP-934 
 
6:4 
 
0.11 ± 
0.016 
840.5 ± 
2.43 
>50 5.68 ± 3.4 0.227 ± 
0.043 
100 ≈ 5-6 
F-6 EC: CP-
934 
8:2 
 
0.11 ± 
0.014 
840.4 ± 
1.46 
>50 4.79 ± 2.2 0.223 ± 
0.025 
100 ≈ 5-6 
 
The total weight for various formulations ranged 
between 839±0.92 to 840.9±1.52 mg (table 2). The 
deviation in the weight was within the limits as it gets 
confirmed by lower values of standard deviation (table 
2). It was observed that the weight of the patches was 
increasing gradually with increase of HPMC content. 
The weight of the patches increased with increase in 
thickness of the respective patches the thickness of the 
patches were increased. The total weight of patches in 
mg/46.57 cm2 was shown in table 2. 
The values of the folding endurance for all the 
formulations are tabulated in table 2. The F-1 and F-2 
patches fabricated by EC and PVP K-30 showed a 
folding endurance of more than 16 and 14 respectively. 
The F-3 and F-4 patches prepared by EC and HPMC 
K15M showed folding endurance more than 10 and 8 
respectively. In comparison with patches made by EC: 
PVP K-30 and EC: HPMC K15M, the patches (F-5 and 
F-6) made of EC and Carbopol showed folding 
endurance more than 50. It can be concluded that the 
patches made of Carbopol were shown better folding 
endurance compared to patches containing PVP K-30 
and HPMC K15M. 
Moisture content studies indicated that the increase in the 
concentration of hydrophilic polymer was directly 
proportional to the increase in moisture content of the 
patches. Moisture content of F-1 and F-2 patches were 
found in the range of 3.17±2.1 to 4.21±3.4% (table 2), 
which showed least moisture content compared to other 
patches. Moisture content of F-3 and F-4 patches were 
found in the range of 4.12±2.9 to 5.06±2.4%, which 
having higher level of moisture content compared to F-1 
and F-2 patches; that may be due to presence of 
hydrophilic nature of HPMC K15M polymer. The 
moisture content of F-5 and F-6 patches was found in the 
range of 4.79±2.2 to 5.68±3.4%; which having greater 
moisture content in comparison to other patches, due to 
presence of more hydrophilic nature of Carbopol 934. 
The moisture content of the prepared formulations was 
low, which could help the formulations remain stable and 
reduce brittleness during long term storage and this could 
protect the formulations from microbial contamination 
and reduce bulkiness. 
For all the formulations, the drug content in area of 0.64 
cm2 was determined and it was shown in between the 
range of 0.210±0.031 to 0.232±0.021mg and which was 
tabulated in table 2. The drug content of all the prepared 
formulations shown that the process employed to prepare 
transdermal patches was capable of giving a uniform 
distribution of drug throughout the whole patches and 
showed minimum batch variability.  
The flatness study showed that all the formulations had 
the same strip length before and after their cuts, 
indicating 100% flatness (table 2). Thus all patches had a 
smooth, flat surface; no constriction and that smooth 
surface could be maintained when the patch was applied 
to the skin. 
Surface pH of the Film: 
 
The surface pH of the polymeric patches ranged between 
5 to 7 (table 2) which falls within the pH range of skin 
i.e. 4.0-6.5. Further, the surface pH data revealed that 
upon increase in Carbopol concentration the surface pH 
of the formulation decreased gradually. Some researchers 
16-18 suggested that excess concentration of Carbopol in 
the formulation may cause irritation to the skin due to its 
acidic nature. That is why formulation containing 
Carbopol, its concentration should be optimized and it 
was further confirmed by conducting the skin irritation 
studies. 
In-Vitro Skin Permeation Study: 
 
Release of the drug from transdermal patches is 
dependent on the physico-chemical properties of the drug 
and physiological & physicochemical properties of the 
biological membrane. In vitro skin permeation 
experiments are known for their value for studying the 
rate and mechanism of percutaneous absorption of drugs. 
In this experiment, variable permeation profiles of 
Carvedilol from the different experimental transdermal 
patches (0.64 cm2) compared with various blends of 
different polymers like EC, PVP K-30, HPMC K-15M 
and Carbopol-934. The percent of drug permeated after 
24 h of the experiments was found between the ranges of 
69.54% to 95.44% (table 3). The percent of drug 
permeated after 24 h was found to be maximum 95.44% 
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and 90.12% from formulation F-5 and F-3 respectively 
(table 3). The process of drug release in most of the 
controlled release device is governed by diffusion and 
the polymer matrix has a strong influence of the 
diffusivity as the motion of small molecules is restricted 
by the three-dimensional network of polymer chains. The 
alteration of the cross linking and the modification of 
structural arrangements of polymers by using different 
blends of polymers already reported. So, different drug 
permeation profiles from various formulations could be 
attributable to the varied cross linking networks of 
polymeric chains of the different blends of polymeric 
transdermal experimental formulations as tortuosity and 
diffusion pathway varied, and they thereby have been 
reported to vary the release of drug and duration of 
diffusion.
  
Table 3:  Percentage (w/w) drug permeated through the rat skin from various transdermal Patches (F-1 to F-6) 
 
Table 4:  Log percentage (w/w) of drug remaining to permeate through the rat skin from various Transdermal 
Patches (F-1 to F-6) 
 
In in-vitro skin permeation experiments also shown as 
the concentration of hydrophilic was increased, the 
amount of drug permeated was concurrently increased. 
This may be a result of the initial rapid dissolution of the 
hydrophilic polymers when the patch is in contact with 
the hydrated skin, which results in accumulation of high 
amount of drugs on the skin surface and thus leads to the 
saturation of the skin with drug molecules at all time. 
The rapid dissolution of the aqueous soluble fraction of 
the film also leads to the formation of pores, and hence 
higher release rate.  
Kinetic Release studies:  
To examine the drug permeation kinetics and 
mechanism, the data were fitted to models representing 
zero-order; first-order, Higuchi and Koresmeyer-Peppas.  
Release of the drug from a transdermal drug delivery 
system mainly involves the factor of diffusion. Diffusion 
is related to the transport of the drugs from a dosage 
matrix into the in vitro study fluid, depending on the 
concentration. As the gradient varies, the drug is released 
and the distance for diffusion becomes increasingly 
greater. This could be an explanation as to why the drug 
diffuses at a slower rate as the distance for diffusion 
increases. The kinetic parameters of drug permeation for 
different formulations were presented in table 5. In this 
experiments the in vitro permeation profiles of all 
formulations did not fit into zero-order (R2 = 0.8754 to 
0.9355) rather they could be best expressed by the first-
order (0.9593 to 0.9977) and Higuchi model (R2 = 0.979 
to 0.9919). The permeation of drug from a homogenous-
polymer matrix type delivery system was mostly 
depended on diffusion characteristics. The percent of 
drug permeated in 24 h was found to be maximum 
95.44% and 90.12% from formulations F-5 and F-3 
respectively. It has been confirm from the table 5, that 
permeation of drug from patches followed both first 
order (R2 =0.9975 and 0.9977) and Higuchi model (R2 = 
0.9909 and 0.9869). The data was further treated as per 
the following equation for confirming the Koresmeyer-
Peppas model: 
Time 
(min) 
SQRT 
(min) 
% Drug Permeated (mg) 
(Mean ± S.D.) 
F-1 F-2 F-3 F-4 F-5 F-6 
0 0 0.000±0.00 0.000±0.00 0.000±0.00 0.000±0.00 0.000±0.00 0.000±0.00 
30 5.47 9.191±1.19 8.042±0.64 13.096±0.82 10.821±0.72 14.035±2.34 11.095±0.31 
60 7.74 16.197±2.18 14.157±1.22 20.038±0.61 17.075±1.14 20.043±1.98 18.482±0.78 
90 9.48 21.067±0.12 19.777±0.65 26.090±0.32 21.856±0.57 27.011±1.06 23.634±0.70 
120 10.95 26.217±0.31 26.802±0.26 32.001±0.52 26.901±0.43 33.056±0.54 28.634±0.56 
150 12.24 29.189±0.75 30.017±0.82 34.014±0.61 30.955±0.72 35.1±0.87 32.099±0.45 
360 18.97 45±0.23 40.877±0.25 50.080±0.85 45.736±0.34 52.00±0.92 47.296±0.99 
1440 37.94 80.916±1.81 69.546±0.57 90.127±0.87 76.835±0.84 95.441±1.00 81.957±0.88 
Time 
(min) 
SQRT 
(min) 
Log (%DRP) (mg) 
(Mean ± S.D.) 
F-1 F-2 F-3 F-4 F-5 F-6 
0 0 0.000±0.00 0.000±0.00 0.000±0.00 0.000±0.00 0.000±0.00 0.000±0.00 
30 5.47 1.958±0.07 1.963±0.02 1.939±0.07 1.950±0.08 1.939±0.01 1.948±0.02 
60 7.74 1.923±0.06 1.933±0.02 1.902±0.06 1.918±0.07 1.902±0.02 1.911±0.09 
90 9.48 1.897±0.06 1.904±0.03 1.868±0.07 1.892±0.09 1.868±0.07 1.884±0.07 
120 10.95 1.867±0.02 1.864±0.04 1.832±0.04 1.863±0.08 1.832±0.09 1.853±0.01 
150 12.24 1.850±0.02 1.844±0.05 1.819±0.03 1.839±0.02 1.819±0.05 1.831±0.02 
360 18.97 1.740±0.04 1.771±0.02 1.698±0.04 1.734±0.06 1.698±0.06 1.721±0.02 
1440 37.94 1.280±0.02 1.483±0.01 0.994±0.05 1.364±0.06 0.994±0.01 1.256±0.01 
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Mt / Mα = K.t
n 
Where, Mt / Mα, is the fractional release of drug, Mt is the 
amount released at time t, Mα is the total amount of drug 
contained in the transdermal film, t is the release time, K 
is a kinetic constant and n is the diffusional release 
exponent indicative of the release mechanism. For Film 
F-3 (n=0.489) and F-5 (n=0.492) has n value near to 0.5, 
it means drug permeation followed Fickian diffusion 
mechanism. n=0.5 stands for Fickian diffusion; and all 
the other patches were also followed Fickian diffusion 
mechanism. When the permeability coefficients (table 6) 
of the different formulations were compared, only F-5 
formulation showed maximum permeability coefficient 
compared to other formulations and the highest level of 
drug permeation through the rat skin. Based on 
physicochemical and in vitro permeation experiments, F-
3 and F-5 chosen for best film, but only F-5 formulation 
was found to have maximum rate of permeation (tables 4 
& 5), maximum steady state flux and maximum 
permeability coefficient (table 6) compared to the 
formulation F-3. 
 
Table 5: Kinetics Models of In Vitro Carvedilol Permeation across Rat Skin from Transdermal Patches 
 
Table 6: Steady State flux (Jss) and Permeability Coefficient (Kp) data of various formulations (F-1 to F-6) 
Formulation  
Code  
Steady State Flux (Jss) 
(mcg.cm
-2
.hr
-1
) 
Mean ± S.D.  
Permeability Coefficient (Kp) 
(cm.hr
-1
)×10
-3
 
Mean ± S.D. 
F-1 0.101±0.007 0.431±0.02 
F-2 0.101±0.006 0.457±0.004 
F-3 0.120±0.002 0.476±0.002 
F-4 0.102±0.006 0.472±0.007 
F-5 0.210±0.001 0.881±0.003 
F-6 0.102±0.004 0.44±0.009 
 
Scanning Electron Microscopy (SEM):
  
Photomicrograph (Figure 1) represents the SEM of blank transdermal film, Carvedilol loaded transdermal film before 
permeation and Carvedilol loaded transdermal film after permeation study of F5 patches respectively. The scanning 
electron micrographs of the drug loaded film clearly indicated that Carvedilol was molecularly dissolved in the polymer 
matrix (figure 1). After completing the permeation study the film (figure 1) showed the presence of pores/channels and 
which indicating the drug permeation was diffusion controlled across rat epidermis. 
 
Figure 1: Scanning Electron Microscopy (SEM) of blank & F-5 transdermal patches: A:  SEM of Blank Transdermal Film (Without 
Drug); B:  SEM of Carvedilol Loaded Transdermal Film (F-5) before Carrying out the Permeation Study & C:  SEM of Carvedilol 
Loaded Transdermal Film (F-5) after Carrying out the Permeation Study. 
Formulation 
Code  
Zero-Order First-Order Higuchi Model Koresmeyer-Peppas 
Model 
k0 (mg.min
-1
) 
 
R
2
 k1 (min
-1
) R
2
 k2 (mg.min
-
1/2
) 
R
2
 N k3 R
2
 
F-1 0.0459 0.9223 0.00115 0.9911 2.1977 0.9919 0.547 0.0211 0.9752 
F-2 0.0381 0.8754 0.00069 0.9593 1.9632 0.9664 0.5397 0.0237 0.938 
F-3 0.0493 0.9287 0.00161 0.9977 2.4942 0.9869 0.489 0.0307 0.9852 
F-4 0.042 0.9029 0.00092 0.9799 2.1583 0.979 0.502 0.0291 0.9799 
F-5 0.0526 0.9355 0.00207 0.9975 2.6172 0.9909 0.4922 0.0297 0.9885 
F-6 0.045 0.9133 0.00115 0.9895 2.2844 0.9834 0.5041 0.0285 0.9774 
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Primary Skin Irritancy Study:
  
The skin irritation test of the formulated patches were 
carried out in comparison with standard and irritant; 
formalin (0.8%). It was carried out by visual observation 
with the help of visual scoring scale. Transdermal 
patches F-3 and F-5 were subjected to skin irritation 
studies. The results showed that F-3 and F-5 
formulations produced negligible signs of erythema, 
edema or ulceration on the skin of albino rabbits after 7 
days. According to some researchers 15-19, compounds 
producing scores of 2 or less are considered negative (no 
skin irritation).  Hence, the developed transdermal 
formulations were free of skin irritation. On the other 
hand, standard irritant, formalin produced severe 
erythema and edema. These results indicate that drug 
does not produce any cutaneous reaction and transdermal 
patches are well tolerated by the subjects.  
Drug-Excipient Interaction Studies:  
The possible drug-excipient interaction study was 
studied by FTIR spectroscopy and DSC  of different 
formulations (F-3 and F-5).
 
Fourier Transform Infrared Spectroscopy:
 
 
In the IR spectra of formulations of F-3 and F-5  the 
major peaks responsible for functional groups like –OH, 
N-H, C-N and C-O-C of Carvedilol slightly altered that 
may be due to formation of weak hydrogen bonding with 
polymers and other excipients  and that was further 
confirmed by DSC studies. 
Differential Scanning Calorimetry:
 
 
The DSC analysis (figure 2)of pure Carvedilol showed a 
sharp exothermic peak at 120.99°C corresponding to its 
melting point of 110°C but in case of final formulations ( 
F-3 and F-5) it was changed slightly as shown in figure 3 
and 4, may be due to weak hydrogen bonding with 
polymers and other excipients.  Although in vitro 
permeation data concluded that it did not seem to 
interfere with the drug permeation from the transdermal 
patches and drug was also in a stable form within the 
patches.
 
 
 
Figure 2: DSC Thermogram of physical mixtures of Carvedilol (CDL), EC and HPMC K15 M. 
 
  
                 Figure 3: DSC Thermograms of F-3 Formulation composed by CDL, EC and HPMC K15M. 
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Figure 4: DSC Thermograms of F-5 Formulation Composed of CDL, EC and Carbopol-934. 
 
X-Ray Diffraction study: 
 
X-ray diffraction study was carried out to reveal the 
crystalline modifications after the preparation of patches. 
Results of x-ray diffractograms for F-3 and F-5 
formulations were studied and compared in respect of 
crystalline modifications with physical mixtures of EC-
HPMC K15M-CDL (PM-1) and EC-CP 934-CDL (PM-
2) respectively. It was shown in figure 5. According to 
diffractograms it was concluded that pure CDL which 
having crystalline form due to more no of peaks, but in 
case of physical mixtures (PM-1 and PM-2) prepared in a 
same ratio of polymers and drugs , shown 2θ values 
32.8854, 41.8848, 43.4429, 48.9334 and 32.9052, 
41.8953, 43.4426, 48.9359 receptively. These prominent 
peaks were not observed in transdermal patches of (F-3 
and F-5), and it may be suppressed due to change of the 
amorphous form.  
  
 
Figure 5: XRD of pure drug CDL, two Best formulations (F-3, F-5) and Corresponding Physical Mixtures (PM-
1, PM-2), F-3; CDL: EC: HPMC K15 M, F-5; CDL: EC: Carbopol 934, PM-1; CDL: EC: HPMC K15 M, PM-2; 
CDL: EC: Carbopol- 934. 
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Stability Study of the Best Formulation:
  
An accelerated stability study contains results regarding 
remaining drug content and physical appearance of best 
formulation i.e. F-5 which concluded that R.D.C. of F-5 
formulation was ranged between 0.227±0.022 to 
0.219±0.045 and physical appearance was also good at 
4°C and 45 °C up to 30 days except in case of 60 °C. At 
60°C the physical appearance was good up to 15 days 
after that film was found hard, rigid and brittle.  From 
stability data it was calculated that the shelf life of the F-
5 formulation was 328.50 days at 25°C. It is therefore 
preferable to store the patches in the refrigerator.  
CONCLUSION 
Transdermal drug delivery system is a most suitable 
system for a long-term treatment or for a multi dose 
treatment, because different transdermal patches are 
prepared for a long period of time in a suitable dose 
proving treatment from a day to even up to seven days. 
In this study Carvedilol transdermal patches were 
prepared with combination of different polymers such as 
EC: PVP K-30, EC: HPMC K-15M, EC: Carbopol-934. 
Total six formulations were selected (F-1 to F-6) for 
further evaluation such as physicochemical properties, 
in-vitro drug permeation study and surface pH of the 
film. From Physicochemical evaluation it is found that 
thickness, weight variation, moisture content, drug 
content, folding endurance and flatness were suitable for 
maximum stability of the prepared transdermal patches. 
In-vitro drug permeation study, the percent of drug 
permeated was found to maximum 95.44 and 90.12% 
from from F-3 and F-5 film respectively. Based on 
physicochemical and in-vitro permeation studies; F-3 
and F-5 were chosen as the best patches among all the 
formulations. F-5 was found to have maximum rate of 
drug permeation, maximum steady state flux and 
maximum permeability coefficient. Through the SEM 
analysis the F-5 film showed the presence of 
pores/channels and it was indicating the diffusion 
controlled permeation of drug across the rat epidermis. 
From the FTIR studies it was concluded that Carvedilol 
slightly altered into the formulated patches and that may 
be due to formation of weak hydrogen bonding with 
polymers and other excipients. It was further confirmed 
by DSC studies. But from in vitro permeation data it can 
be concluded that it did not seem to interfere with the 
drug permeation from the transdermal patches and drug 
was also in a stable form within the patches. According 
to XRD diffractograms it was concluded that pure CDL 
was in crystalline form due to more no of peaks. In case 
of physical mixtures (PM-1 and PM-2) prepared in a 
same ratio of polymers and drugs , showed 2θ values 
32.8854, 41.8848, 43.4429, 48.9334 and 32.9052, 
41.8953, 43.4426, 48.9359 receptively. The major peaks 
were disappeared in transdermal patches of   F-3 and F-5 
and it may be suppressed due to changes of the 
polymorphic amorphous form. According to primary 
skin irritancy study, results indicated that drug did not 
produce any cutaneous reaction and transdermal patches 
are well tolerated by the subjects. The stability study 
concluded that the shelf life of the F-5 formulation was 
328.50 days at 25°C. It is therefore preferable to store the 
film in the refrigerator. In view of the encouraging 
results obtained, further clinical studies can be carried 
out using the best obtained formulation on healthy 
human volunteers. 
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